Evidence map›Paper›PMID 23240761›Full record

Trial reportBritish journal of haematology2013

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, Thomas Caughey, Federico Campigotto, Rachel Rosovsky, Simon Mantha, Craig M Kessler, Jonathan Eneman, Vidya Raghavan and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00908960 (A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles), which is not on this map. Cited by 45 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00908960 phase2completednot on this map

A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2009 to 2012Enrolled70ConditionsAdvanced Pancreatic, Colon, Lung, Gastric and Ovarian CancerArmsEnoxaparin
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Anticoagulation for perioperative thromboprophylaxis in people with cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Pooled it
  8. Anticoagulation for people with cancer and central venous catheters.The Cochrane database of systematic reviews · 2018
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Parenteral anticoagulation in ambulatory patients with cancer.The Cochrane database of systematic reviews · 2017
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Global research status and trends in venous thromboembolism and pancreatic cancer: a bibliometric analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  16. Article
  17. Review
  18. Observational
  19. The theragnostic advances of exosomes in managing leukaemia.Journal of cellular and molecular medicine · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jeffrey I ZwickerDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. jzwicker@bidmc.harvard.edu
Howard A Liebman
Kenneth A Bauer
Thomas Caughey
Federico Campigotto
Rachel Rosovsky
Simon Mantha
Craig M Kessler
Jonathan Eneman
Vidya Raghavan
Heinz-Joseph Lenz
Andrea Bullock
Elizabeth Buchbinder
Donna Neuberg
Bruce Furie

Funding

Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
Cancer, venous thromboembolic disease and tissue factor-bearing microparticlesR01HL095084 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FURIE, BRUCE · 2008 to 2012
$2.1M
Bloodborne tissue factor-bearing microparticles in Trousseau's syndromeK23HL084052 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZWICKER, JEFFREY · 2007 to 2011
$747k
NCATS NIH HHS UL1 TR000130NHLBI NIH HHS K23 HL084052NHLBI NIH HHS K23 HL84052NHLBI NIH HHS L30 HL074959NHLBI NIH HHS R01 HL095084
6 · The paper itself

Abstract

Elevated levels of circulating tissue factor-bearing microparticles (TFMP) have been associated with an increased risk of developing venous thromboembolism (VTE) in cancer patients. We performed a randomized phase II study to evaluate the cumulative incidence of VTE in advanced cancer patients with lower levels of TFMP not receiving thromboprophylaxis and those with higher levels of circulating TFMP randomized to enoxaparin or observation. The cumulative incidence of VTE at 2 months in the higher TFMP group randomized to enoxaparin (N = 23) was 5·6% while the higher TFMP group observation arm (N = 11) was 27·3% (Gray test P = 0·06). The cumulative incidence of VTE in the low TFMP was 7·2% (N = 32). No major haemorrhages were observed in the enoxaparin arm. The median survival for patients with higher levels of TFMP followed by observation was 11·8 months compared with 17·8 months on enoxaparin (P = 0·58). In a prospective randomized trial, increased numbers of circulating TFMP detected by impedance flow cytometry identified cancer patients with a high incidence of VTE. Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate of VTE similar in magnitude to the lower TFMP group.

Indexed as

AgedAged, 80 and overAnticoagulantsCell-Derived MicroparticlesEnoxaparinFemaleFibrin Fibrinogen Degradation ProductsHumansMaleMiddle AgedNeoplasmsSurvival AnalysisThromboembolismThromboplastinAnticoagulantsEnoxaparinFibrin Fibrinogen Degradation Productsfibrin fragment DThromboplastin

Identifiers

PMID23240761
PMCPMC3609903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.